Jump to content
Sign in to follow this  

Entacapona sin riesgo cardiovascular

Recommended Posts

Una revisión de la FDA no encontró evidencia clara de un aumento de riesgo en ataques al corazón, de embolias cerebrales u otros eventos cardiovasculares asociados con el uso de entacapona para el tratamiento del Parkinson.




La entacapona que puede encontrarse como Comtan o junto con carbidopa/levodopa como Stalevo, puede seguir utilizándose con las mismas recomendaciones. 





Twitter: @drdanielmtz

Edited by drdanielmtz
  • Like 1

Share this post

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • Create New...